Chartwell Investment Partners LLC Buys 246,594 Shares of Haleon plc (NYSE:HLN)

Chartwell Investment Partners LLC increased its position in Haleon plc (NYSE:HLN - Free Report) by 107.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 475,415 shares of the company's stock after purchasing an additional 246,594 shares during the period. Chartwell Investment Partners LLC's holdings in Haleon were worth $5,030,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HLN. Manning & Napier Advisors LLC bought a new stake in shares of Haleon during the 2nd quarter valued at about $2,833,000. First Eagle Investment Management LLC lifted its holdings in shares of Haleon by 31.0% in the 1st quarter. First Eagle Investment Management LLC now owns 1,361,021 shares of the company's stock worth $11,555,000 after purchasing an additional 321,928 shares during the last quarter. Orion Portfolio Solutions LLC boosted its position in Haleon by 25.1% during the 1st quarter. Orion Portfolio Solutions LLC now owns 694,524 shares of the company's stock valued at $5,897,000 after purchasing an additional 139,263 shares during the period. Sei Investments Co. boosted its position in Haleon by 79.1% during the 1st quarter. Sei Investments Co. now owns 781,089 shares of the company's stock valued at $6,632,000 after purchasing an additional 345,036 shares during the period. Finally, Magnetar Financial LLC bought a new position in Haleon during the 1st quarter worth $853,000. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

NYSE HLN traded down $0.23 during trading hours on Tuesday, reaching $9.28. 7,516,344 shares of the company's stock were exchanged, compared to its average volume of 5,241,707. The firm has a fifty day moving average of $10.18 and a 200-day moving average of $9.32. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The stock has a market cap of $42.01 billion, a PE ratio of 27.97, a price-to-earnings-growth ratio of 2.90 and a beta of 0.30.

Analysts Set New Price Targets

HLN has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a "buy" rating for the company. Finally, Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.